EHA-SWG Scientific meeting on Immunotherapy: Checkpoint inhibition in hematologic malignancies

  Dec 03 2020 Tagged ICI

The EHA-SWG Scientific Meetings are designed to create a high quality scientific program and to share in-depth scientific knowledge with hematologists around the world. The most recent meeting dedicated to Immunotherapy covered all the innovative therapeutic options based on manipulation of the immunity system available or in development for patients with hematologic malignancies.  

Selected from the extensive meeting program, in this article we present two lectures addressing the role of immune checkpoint inhibitors (ICIs) in hematology. Results from clinical trials of checkpoint blockade in hematologic malignancies suggest the therapeutic usefulness of this approach across several tumor types, and the potential change of the treatment landscape in some diseases, such as Hodgkin lymphoma. 

The mechanism of action and biologic rationale of PD-1/PD-L1 and CTLA-4 inhibitors are discussed by Peter Brossart and the currently FDA/EMA approved hematologic indications and emerging perspective by Paul Bröckelmann. Watch the sessions by clicking on the videos below. (Stay tuned - More educational videos will be available in the next weeks!)

Peter Brossart (DE) | Checkpoint inhibitors (CPI): Mechanism of action

Paul Bröckelmann (DE) | Checkpoint Inhibition in Hematologic Malignancies: Approved and Emerging Indications


Last Updated on Thursday 03 December 2020.